Marex Group’s ANI Pharmaceuticals ANIP Stock Holding History

Marex Group’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,265	Closed	-$258K	–	1022
2025 Q4	$258K	Buy	+3,265	New	+$283K	﹤0.01%	755

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

GAM

Goldentree Asset Management New York $1.72B AUM 1.39% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Marex Group's ANIP Position: Q1 2026 in Review

Marex Group sold out of ANI Pharmaceuticals (ANIP) in Q1 2026, closing a stake of 3,265 shares — an estimated $258K sold.

Marex Group first reported a position in ANIP in Q4 2025 and held it in 1 quarter. The position peaked at $258K in Q4 2025. 281 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

Marex Group reported no remaining ANI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Marex Group sold 3,265 ANI Pharmaceuticals shares in Q1 2026, an estimated $258K.
Marex Group first reported a position in ANI Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Marex Group's ANI Pharmaceuticals position peaked at $258K in Q4 2025.
281 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.